| Literature DB >> 31727504 |
Jasmin Federizon1, Amber Frye2, Wei-Chiao Huang1, Thomas M Hart3, Xuedan He1, Christopher Beltran4, Ashley L Marcinkiewicz4, Iain L Mainprize5, Melanie K B Wills5, Yi-Pin Lin2, Jonathan F Lovell6.
Abstract
Outer surface protein A (OspA) is a Borrelia lipoprotein and an established Lyme disease vaccine target. Admixing non-lipidated, recombinant B. burgdorferi OspA with liposomes containing cobalt porphyrin-phospholipid (CoPoP) resulted in rapid, particulate surface display of the conformationally intact antigen. Particleization was serum-stable and led to enhanced antigen uptake in murine macrophages in vitro. Mouse immunization using CoPoP liposomes that also contained a synthetic monophosphoryl lipid A (PHAD) elicited a Th1-biased OspA antibody response with higher IgG production compared to other vaccine adjuvants. Antibodies were reactive with intact B. burgdorferi spirochetes and Borrelia lysates, and induced complement-mediated borreliacidal activity in vitro. One year after initial immunization, mice maintained high levels of circulating borreliacidal antibodies capable of blocking B. burgdorferi transmission from infected ticks to human blood in a feeding chamber.Entities:
Keywords: Adjuvant; Liposomes; Lyme disease; OspA; Particle vaccine
Year: 2019 PMID: 31727504 PMCID: PMC6980772 DOI: 10.1016/j.vaccine.2019.10.073
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641